Cervical cancer screening with both human papillomavirus and Papanicolaou testing vs Papanicolaou testing alone: what screening intervals are physicians recommending?
- PMID: 20548011
- DOI: 10.1001/archinternmed.2010.134
Cervical cancer screening with both human papillomavirus and Papanicolaou testing vs Papanicolaou testing alone: what screening intervals are physicians recommending?
Abstract
Background: Guidelines recommend screening for cervical cancer among women 30 years or older 3 years after a normal Papanicolaou test (hereinafter referred to as Pap test) result or a combined normal screening result (normal Pap/negative human papillomavirus [HPV] test results). We assessed reported recommendations by US primary care physicians (PCPs) on screening intervals that incorporate HPV cotesting compared with Pap testing alone.
Methods: From September 1, 2006, through May 31, 2007, we conducted a mailed survey of a representative sample of 1212 PCPs, of whom 950 performed Pap tests and recommended the HPV test for screening or management. The main outcome measure included self-reported data on timing of screening intervals for women with normal results using clinical vignettes.
Results: Among Pap test providers who recommend HPV testing, 31.8% reported that they would conduct the next Pap test in 3 years for a 35-year-old woman with 3 normal Pap test results. For a 35-year-old woman with a normal Pap test result and a negative HPV test finding, only 19.0% would conduct the next Pap test in 3 years. Most remaining physicians would conduct the Pap test more frequently. Most PCPs did not recommend a second HPV test or recommended the next HPV test at the same frequency as the Pap test. Physician specialty was strongly associated with guideline-consistent recommendations for the next Pap or HPV test.
Conclusions: A lower proportion of PCPs recommend extending screening intervals to 3 years with an HPV cotest than those screening with the Pap test alone. Implementation of effective interventions and strategies that improve physician adherence to recommendations will be important for efficient screening practices.
Comment in
-
Rightsizing cervical cancer screening: comment on "Cervical cancer screening with both human papillomavirus and Papanicolaou testing vs Papanicolaou testing alone".Arch Intern Med. 2010 Jun 14;170(11):985-6. doi: 10.1001/archinternmed.2010.133. Arch Intern Med. 2010. PMID: 20548012 No abstract available.
Similar articles
-
Rightsizing cervical cancer screening: comment on "Cervical cancer screening with both human papillomavirus and Papanicolaou testing vs Papanicolaou testing alone".Arch Intern Med. 2010 Jun 14;170(11):985-6. doi: 10.1001/archinternmed.2010.133. Arch Intern Med. 2010. PMID: 20548012 No abstract available.
-
Human papillomavirus and Papanicolaou tests screening interval recommendations in the United States.Am J Obstet Gynecol. 2011 Nov;205(5):447.e1-8. doi: 10.1016/j.ajog.2011.06.001. Epub 2011 Jun 12. Am J Obstet Gynecol. 2011. PMID: 21840492
-
Impact of pap test compliance and cervical cancer screening intervals on human papillomavirus vaccine acceptance.J Low Genit Tract Dis. 2012 Jan;16(1):39-44. doi: 10.1097/LGT.0b013e31822e8e25. J Low Genit Tract Dis. 2012. PMID: 22126831
-
Human papillomavirus testing for primary cervical cancer screening.Expert Rev Mol Diagn. 2008 Sep;8(5):599-605. doi: 10.1586/14737159.8.5.599. Expert Rev Mol Diagn. 2008. PMID: 18785808 Review.
-
Cervical cancer screening in the early post vaccine era.Obstet Gynecol Clin North Am. 2008 Dec;35(4):537-48; vii. doi: 10.1016/j.ogc.2008.09.005. Obstet Gynecol Clin North Am. 2008. PMID: 19061815 Review.
Cited by
-
Primary care Providers' approaches to cervical cancer screening in Muslim females.Prev Med Rep. 2023 Feb 4;32:102126. doi: 10.1016/j.pmedr.2023.102126. eCollection 2023 Apr. Prev Med Rep. 2023. PMID: 36852309 Free PMC article.
-
Women's acceptability of and experience with primary human papillomavirus testing for cervix screening: HPV FOCAL trial cross-sectional online survey results.BMJ Open. 2021 Oct 7;11(10):e052084. doi: 10.1136/bmjopen-2021-052084. BMJ Open. 2021. PMID: 34620663 Free PMC article.
-
Overuse of Cervical Cancer Screening Tests Among Women With Average Risk in the United States From 2013 to 2014.JAMA Netw Open. 2021 Apr 1;4(4):e218373. doi: 10.1001/jamanetworkopen.2021.8373. JAMA Netw Open. 2021. PMID: 33914050 Free PMC article.
-
Incorporating Stakeholder Feedback in Guidelines Development for the Management of Abnormal Cervical Cancer Screening Tests.J Low Genit Tract Dis. 2020 Apr;24(2):167-177. doi: 10.1097/LGT.0000000000000524. J Low Genit Tract Dis. 2020. PMID: 32243312 Free PMC article.
-
Nationwide Epidemiological Study of Knowledge, Attitudes, and Practices Study of Greek General Practitioners Related to Screening.Int J Prev Med. 2019 Nov 6;10:199. doi: 10.4103/ijpvm.IJPVM_46_17. eCollection 2019. Int J Prev Med. 2019. PMID: 31772731 Free PMC article.
